한빛사논문
- 조회399
Kai Bao 1, Molly Tully 1, Kevin Cardenas 1, Haoran Wang 1, Surbhi Srinivas 1, Jiyun Rho 1,2, Ok Hwa Jeon 2, Jason Dinh 1, Shinya Yokomizo 1, Rose McDonnell 1, Atsushi Yamashita 1, Satoshi Kashiwagi 1, Homan Kang 1, Hyun Koo Kim 2, Hak Soo Choi 1
1Gordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA.
2Department of Biomedical Sciences and Department of Thoracic and Cardiovascular Surgery, Korea University Guro Hospital, College of Medicine, Korea University, Seoul, 08308, South Korea.
CORRESPONDING AUTHORS : Hyun Koo Kim, Hak Soo Choi
Abstract
Two of the most pressing challenges facing bioimaging are nonspecific uptake of intravenously administered contrast agents and incomplete elimination of unbound targeted agents from the body. Designing a targeted contrast agent that shows fast clearance from background tissues and eventually the body after complete targeting is key to the success of image-guided interventions. Here, this work describes the development of renally clearable near-infrared contrast agents and their potential use for dual-channel image-guided tumor targeting. cRGD-ZW800-PEG (800 nm channel) and ZW700-PEG (700 nm channel) are able to visualize tumor margins and tumor vasculature simultaneously and respectively. These targeted agents show rapid elimination from the bloodstream, followed by renal clearance, which together significantly lower off-target background signals and potential toxicity. To demonstrate its applicability, this multispectral imaging is performed in various tumor-bearing animal models including lung cancer, pancreatic neuroendocrine tumors, breast, and ovarian cancer.
논문정보
- Research article
- 2023년 01월 (BRIC 등록일 2023-02-23)
- 국내(교신)+국외 연구진
- 바이오·의료융합 > 바이오센싱 및 나노바이오물질
댓글 작성 로그인
팝업 닫기관련 링크
연구자 키워드
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
